Cognition Therapeutics Inc (NASDAQ:CGTX) shares, rose in value on Thursday, July 10, with the stock price up by 31.45% to the previous day’s close as strong demand from buyers drove the stock to $0.7.
Actively observing the price movement in the last trading, the stock closed the session at $0.53, falling within a range of $0.6501 and $1.04. The value of beta (5-year monthly) was 0.739. Referring to stock’s 52-week performance, its high was $2.54, and the low was $0.22. On the whole, CGTX has fluctuated by 131.46% over the past month.
With the market capitalization of Cognition Therapeutics Inc currently standing at about $43.38 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-07.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CGTX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of CGTX currently trading nearly 91.54% and 103.08% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 79.05, while the 7-day volatility ratio is showing 32.69% which for the 30-day chart, stands at 14.69%. Furthermore, Cognition Therapeutics Inc (CGTX)’s beta value is 0.88.
A comparison of Cognition Therapeutics Inc (CGTX) with its peers suggests the former has fared considerably weaker in the market. CGTX showed an intraday change of 31.45% in last session, and over the past year, it shrunk by -0.23%%.
Data on historical trading for Cognition Therapeutics Inc (NASDAQ:CGTX) indicates that the trading volumes over the past 10 days have averaged 32.13 and over the past 3 months, they’ve averaged 2.30 million. According to company’s latest data on outstanding shares, there are 61.97 million shares outstanding.
Nearly 19.35% of Cognition Therapeutics Inc’s shares belong to company insiders and institutional investors own 9.13% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.54 million shares as on 2025-06-13, resulting in a short ratio of 0.98. According to the data, the short interest in Cognition Therapeutics Inc (CGTX) stood at 276.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 1.34 million. The stock has fallen by -62.78% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CGTX stock heading into the next quarter.
